10 “Strong Buy” Healthcare Stocks With Over 100% Upside Potential According to Top Analysts

With so many people giving investment advice online, it can seem that you only need an email address to become a financial influencer.

Meanwhile, financial analysts with a proven track record carefully research companies and produce detailed reports with their recommendations and reasoning behind them.

The TipRanks stock screener enables investors to easily search for stocks according to different criteria. These include the analyst consensus and price targets of the top-performing Wall Street analysts. We used it to search for stocks with the highest upside potential as we head towards May 2021.

Why Healthcare Stocks?

When using the TipRanks screener to search for stocks with the highest upside potential according to the best performing analysts. Healthcare stocks dominated the results.

All the stocks on the list have either a small market cap ($300M – $2B) or a micro-market cap (under $300M). Many of them are penny stocks which although can offer opportunities for outsized returns, are known to be volatile.

Top 10 Healthcare Stocks According to The Best Analysts

BiomX (PHGE)

BiomX develops treatments for bacteria that affect the skin and that cause harm in chronic diseases such as cystic fibrosis.

Its average price target of $22.50 indicates 241.43% upside according to the best performing analysts. All 4 analysts who rate the stock have a Buy rating. 3 out of the 4 of the analysts made their rating in the past month.

Aveo Pharmaceuticals (AVEO)

Aveo is a biopharmaceutical company that engages in the advancement of oncology therapeutics. Its lead candidate received approval by the FDA in March 2021.

With an average price target of $22.33 the top performing analysts see 218.54% upside potential over the next 12 months.

All analysts who rate the stock have a 4 or 5-star ranking.

Cardiff Oncology, Inc. (CRDF)

A clinical-stage company, Cardiff Oncology seeks to develop new treatments for cancer patients.

It has 5 Buy ratings from top performing analysts, with no hold or sell ratings and an average price target of $27.33 which translates into upside potential of 214.50%.

It’s not just analysts backing the stock. A closer look shows that company insiders, those who are arguably most in the know, have been making informative buys. As with analysts, TipRanks ranks insiders.

Veru (VERU)

An oncology biopharmaceutical company, Veru develops novel medicines for two common forms of cancer – prostate and breast cancer.

In addition to having 4 Buy ratings from analysts and an average price target of $25.00, indicating 165.11% upside, hedge funds have also being buying Veru stocks.

Last quarter hedge funds increased their holding in the company by 1.6M Shares.

Gamida Cell Ltd (GMDA)

Gamida Cell Ltd develops cell therapies for blood cancers and serious blood disorders. In March 2021 the company announced the results of a Phase 3 clinical study.

The stock has 10 Buy ratings, 5 were issued in the past month and H.C. Wainwright’s Vernon Bernardino reiterated a Buy rating less than two weeks ago. It has an average price target of $20.00 which shows 154.78% upside potential.

TipRanks investors are also bullish on the stock with a 7.6% increase in the number of portfolios of the best performing investors adding GMDA to their Smart Portfolios in the last 7 days.

CymaBay Therapeutics (CBAY)

CymaBay is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of new medicines for liver and other chronic diseases.

The best performing analysts have an average price target of $11.50 on the stock, 147.31% upside.

In the past three months 6 top performing analysts have issued Buy ratings for the stock, with no Hold or Sell ratings. It has 10 Buy ratings overall.

G1 Therapeutics Inc (GTHX)

G1 Therapeutics is a biopharmaceutical company that specializes in small molecule therapeutics for the treatment of patients with cancer. The company just announced final pooled results from three clinical trials.

With a $55.60 average price target, the best performing analysts predict 144.07% upside. Five top analysts have issued Buy ratings on the stock in the past 3 months.

Cormedix (CRMD)

The Cormedix company develops a novel, antimicrobial and antifungal solution for the prevention of catheter-related bloodstream infections in patients with end-stage renal disease.

In February 2021 the stock’s value was $17.58. The price has since slumped, however analysts are optimistic. The average price target of top analysts is $19.38, an increase of 125.61%. 5 analysts have made a Buy rating in the past month.  

Rigel (RIGL)

Rigel is a biotechnology company that develops small molecule drugs for patients with hematologic disorders, cancer, and rare immune diseases.

Top analysts have set an average price target of $8.75, indicating 24.36% potential upside.

KalVista Pharmaceuticals Inc (KALV)

KalVista is a pharmaceutical company that works on small molecule protease inhibitors to treat diseases.

All 6 recent ratings by top analysts are Buy and the average price target of $54.33 represents 110.58% upside.

About the Search

We looked for healthcare stocks with a “Strong Buy” rating consensus and 1-year price target of over 20% according to the best performing analysts. To ensure we only pulled up stocks with other positive indicators, we also focused on stocks with an “Outperform” Smart Score of 8, 9, or 10 out of 10. This data-driven score measures stocks on 8 key market factors. It’s worth noting that all price targets are based on ratings made within the past 3 months.

How Does TipRanks Measure Analyst Performance?

TipRanks measures analysts according to three different factors – success rate, average return per rating, and statistical significance. Analysts who have made more stock recommendations are likely to be ranked higher.

5-star analysts have the best success rates, average returns, and a high transaction count. TipRanks also shows you how analysts are ranked overall, including compared to different benchmarks, such as sector, S&P 500, or different time frames.

Disclaimer: The content is for informational purposes only. It does not constitute advice nor recommendations. It is very important to do your own analysis before making any investment.